PIN77 EFFICACY MISAPPLICATION IN VACCINE MODELLING by Sutton, K., Aponte Ribero, V., Roiz, J.

Get full text

POSB304 Quo Vadis Hyt: A Comparison of Hyt and Qalys in HER2+ Breast Cancer by Bührer, C, Jovanoski, N, Aponte Ribero, V, Ray, J

Get full text

EE421 Burden of Illness Related to Motor Function in Types 2 and 3 Spinal Muscular Atrophy (SMA) by Sutherland, CS, Aponte Ribero, V, Hoffart, J, Gravestock, I, Servais, L

Get full text

CO135 Matching-Adjusted Indirect Comparison of Risdiplam Versus Nusinersen in Type 1 Spinal Muscular Atrophy: 2-Year Update by Marti-Gil, Y, Aponte Ribero, V, Gorni, K, Daigl, M, Evans, R, Scott, DA, Mahajan, A, Hawkins, N

Get full text

EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Musc... by Boussahoua, M, Sutherland, CS, Aponte Ribero, V, Enache, R, Le Lay, K, Le Dissez, C, Chevalier, J

Get full text

PND77 Spinal Muscular Atrophy Type 1: Estimation of Survival by Aponte Ribero, V., Sutherland, C.S., Gorni, K., Mitchell, S., Batson, S.

Get full text

POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China by Hu, J, Sutherland, CS, Aponte Ribero, V, Zhu, L, Hou, X, Xia, Y, Tang, M, Jin, C, Kang, Q

Get full text